Observational study in AIDS research and human retroviruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 8 institutions in 1 country.
Mary Clare MastersDepartment of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0002-8419-6105
Janeway GrancheCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Jingyan YangInstitute for Social and Economic Research and Policy, Columbia University, New York, New York, USA.
Edgar T OvertonDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Scott LetendreDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
Susan L KoletarDepartment of Internal Medicine, Ohio State University, Columbus, Ohio, USA.
Leah H RubinDepartment of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0003-2749-6328
Todd T BrownDepartment of Medicine, Johns Hopkins University, Maryland, USA.ORCID 0000-0001-8599-278X
Katherine TassiopoulosCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Kristine M ErlandsonDepartment of Medicine, University of Colorado, Aurora, Colorado, USA.ORCID 0000-0003-0808-6729
Frank PalellaDepartment of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Cancer Research And Biostatistics · USJohns Hopkins University · USNorthwestern University · USColumbia University · USThe Ohio State University · USUniversity of Alabama at Birmingham · USUniversity of California San Diego · USUniversity of Colorado Anschutz Medical Campus · US
Funding
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related InfectionsUM1AI068636 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 to 2025
$229.0M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2021 to 2025
$81.6M
AIDS Clinical Trial Group Laboratory CenterUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 to 2025
$54.5M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials UnitUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · 2021 to 2025
$23.6M
UCSD Collaborative Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2021 to 2025
$18.1M
Pitt-Ohio State Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2021 to 2025
$13.1M
Clinical and Translational Science CenterUL1TR002384 · WEILL MEDICAL COLL OF CORNELL UNIV · 2025 to 2025
$9.8M
Chicago Clinical Trials UnitUM1AI069471 · NIAID · NORTHWESTERN UNIVERSITY · 2021 to 2025
$5.9M
Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC CenterU01HL146201 · JOHNS HOPKINS UNIVERSITY · 2025 to 2025
$4.0M
Mentoring in Endocrine and Metabolic Abnormalities in HIV and AgingK24AI120834 · JOHNS HOPKINS UNIVERSITY · 2025 to 2025
Older persons with HIV (PWH) experience high rates of cognitive impairment and frailty, and accelerated decline in physical function compared with the general population. Metformin use has been associated with beneficial effects on cognitive and physical function among older adults without HIV. The relationship between metformin use on these outcomes in PWH has not been evaluated. AIDS Clinical Trials Group (ACTG) A5322 is an observational cohort study of older PWH with annual assessments for cognition and frailty, including measures of physical function (e.g., gait speed and grip strength). Participants with diabetes who were prescribed antihyperglycemic medications were included in this analysis to evaluate the association between metformin and functional outcomes. Cross-sectional, longitudinal, and time-to-event models were used to evaluate the relationship between metformin exposure with cognitive, physical function, and frailty outcomes. Ninety-eight PWH met inclusion criteria and were included in at least one model. No significant associations between metformin use, frailty, physical, or cognitive function were noted in unadjusted or adjusted cross-sectional, longitudinal, or time-to-event models (
Indexed as
Diabetes MellitusFrailtyHIV InfectionsMetforminAgedAged, 80 and overCognitionCross-Sectional StudiesHumansMetforminagingfrailtyHIVmetforminphysical function
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Association Between Metformin Use and Cognitive and Physical Function in Persons with HIV and Diabetes. · full record | Socratic